See more : Vista Energy, S.A.B. de C.V. (VISTAA.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Tyme Technologies, Inc. (TYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyme Technologies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- AB Electrolux (publ) (ELUX-A.ST) Income Statement Analysis – Financial Results
- Marel hf. (MAREL.IC) Income Statement Analysis – Financial Results
- YANGAROO Inc. (YOO.V) Income Statement Analysis – Financial Results
- Colbún S.A. (COLBUN.SN) Income Statement Analysis – Financial Results
- Artini Holdings Limited (0789.HK) Income Statement Analysis – Financial Results
Tyme Technologies, Inc. (TYME)
About Tyme Technologies, Inc.
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.44M | 17.03M | 12.96M | 14.72M | 8.84M | 6.11M | 3.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Other Expenses | 2.44M | 0.00 | 0.00 | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.20K |
| Operating Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | -2.10K |
| Cost & Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | 2.10K |
| Interest Income | 0.00 | 22.08K | 229.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 70.24K | 97.13K | 114.24K | 0.00 | 0.00 | 0.00 | 3.50M | 76.56K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.96M | 5.18K | 5.18K | 8.42K | 4.30K | 4.28K | 4.29K | 76.56K | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.56M | -27.22M | -25.76M | -31.78M | -19.36B | -15.21B | -8.60M | 22.65K | -56.59K | -27.43K | -2.10K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.51M | -27.22M | -25.76M | -31.78M | -19.36M | -15.21M | -8.60M | -53.91K | -56.59K | -27.43K | -2.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.89M | -1.76M | 3.76M | -1.21M | 19.34B | 15.19B | -3.13M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -23.63M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.96M | -1.66M | 3.87M | -1.21M | 390.39K | 0.00 | 376.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -21.67M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
| Weighted Avg Shares Out (Dil) | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
3 Penny Stocks To Watch Under $2 Making Big Moves Today
TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting
Why Tyme Stock Got Demolished Today
TYME Stock Price Falls Over 25% Pre-Market: Why It Happened
TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results
TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
TYME Stock Price Increases Over 100%: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports